Latest news with #Zaltenibart
Business Wire
12-05-2025
- Business
- Business Wire
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the 'Call Me' option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN. A replay of the call will be made accessible online at About Omeros Corporation Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. Zaltenibart, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in clinical development for treatment of paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit
Yahoo
12-05-2025
- Business
- Yahoo
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
SEATTLE, May 12, 2025--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the "Call Me" option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN. A replay of the call will be made accessible online at About Omeros Corporation Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. Zaltenibart, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in clinical development for treatment of paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit View source version on Contacts Jennifer Cook WilliamsCook Williams Communications, and Media RelationsIR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-03-2025
- Business
- Yahoo
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
SEATTLE, March 26, 2025--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the "Call Me" option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN. A replay of the call will be made accessible online at About Omeros Corporation Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. Zaltenibart, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit View source version on Contacts Jennifer Cook WilliamsCook Williams Communications, and Media RelationsIR@ Sign in to access your portfolio
Associated Press
26-03-2025
- Business
- Associated Press
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
SEATTLE--(BUSINESS WIRE)--Mar 26, 2025-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the 'Call Me' option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN. A replay of the call will be made accessible online at About Omeros Corporation Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. Zaltenibart, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit Cook Williams Communications, Inc. SOURCE: Omeros Corporation Copyright Business Wire 2025. PUB: 03/26/2025 09:15 AM/DISC: 03/26/2025 09:15 AM
Yahoo
24-03-2025
- Business
- Yahoo
Omeros to activate site for Phase III programme of zaltenibart for PNH
Omeros has announced that the activation of clinical trial sites for patient enrolment is now in progress for its Phase III programme of the human monoclonal antibody zaltenibart for treating paroxysmal nocturnal haemoglobinuria (PNH). Zaltenibart, also known as OMS906, is an investigational mannan-binding lectin-associated serine protease-3 (MASP-3) inhibitor. The Phase III programme will involve 120 clinical investigative sites across 30 nations, with a significant number already having detected potential PNH patient participants. Omeros is actively working with these sites to further identify eligible subjects for the trials of the antibody. The data required for the biologics licencing application (BLA) and worldwide approval dossiers are underway for the fourth quarter of 2026. The Phase III trials are set to assess the antibody's intravenous form dosed one time for every eight-week period. Omeros' comprehensive Phase III programme comprises two clinical trials: one for subjects not on complement-inhibitor treatment at study entry and another for those without an adequate response to complement component 5 (C5) inhibitors, ravulizumab or eculizumab treatment. These two trials are designed to compare the antibody's safety and efficacy as a single agent against these C5 inhibitors, with regulatory approval received from both the Food and Drug Administration (FDA) and European authorities for the trial designs. Omeros has already manufactured the antibody drug product needed for the Phase III programme and has sourced the necessary comparator C5 inhibitors. The head-to-head study designs aim to show the antibody's 'superiority' over C5 inhibitors. Omeros Corporation CEO and chairman Gregory Demopulos said: 'All of us at Omeros are pleased that the Phase III clinical programme for zaltenibart is well underway. 'The zaltenibart Phase II data have demonstrated important differentiators from currently marketed agents, and we expect those same advantages to be evidenced in the Phase III trials, which are similar in design to our Phase II trials.' In a move to prepare for the commercialisation of the antibody, the German Federal Joint Committee, a decision-making body, provided recommendations on patient-reported-outcome measures. These recommendations have been 'incorporated' into the antibody's Phase III design, which could be instrumental in achieving appropriate pricing. "Omeros to activate site for Phase III programme of zaltenibart for PNH" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
